The LeaderMed team’s expertise allows them to advance and obtain regulatory approvals for new drugs in China and the Asia-Pacific region faster than what can be secured in the U.S. and Europe.
In the China and Asia-Pacific markets our team members have led over 60 trials for innovative drugs; co-founded a CRO; led over 10 successful NDAs; and commercialized over $3 billion in global drug sales and medical devices, benefitting patients in over 50 countries.
Shared 6 days ago
10 views
Shared 3 months ago
72 views
Shared 3 months ago
414 views
Shared 6 months ago
214 views
Shared 7 months ago
306 views
Shared 10 months ago
523 views
UltraSculpt: The Only Non-Invasive Fat Reduction That Boosts Metabolic Health, Dr. Goldfarb Explains
Shared 1 year ago
94 views
Shared 1 year ago
35 views
Shared 1 year ago
236 views
Shared 1 year ago
41 views
Shared 1 year ago
15 views
Shared 1 year ago
21 views
Shared 2 years ago
100 views
Shared 2 years ago
185 views
Shared 2 years ago
56 views
Shared 2 years ago
79 views
Shared 2 years ago
38 views
Shared 2 years ago
30 views